Phase II evaluation of metoprine with leucovorin rescue in patients with advanced colorectal carcinoma.
In a phase II trial 24 patients with measurable metastatic colorectal carcinoma were treated every 2 weeks with high-dose metoprine at 175 mg/m2 and leucovorin rescue. Hematologic toxicity was mild; the limiting toxicity was CNS, occurring in 54% of the patients. No responses were observed, but four patients had disease stabilization. High-dose metoprine with leucovorin rescue appears ineffective in previously treated patients with colorectal carcinoma in the dose and schedule used in this study.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011739:Pyrimethamine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012004:Rectal Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; C006308:metoprine; D002955:Leucovorin; D011739:Pyrimethamine